AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Amgen
Amgen
Pfizer
Amgen
Celgene
Celgene
Celgene
Celgene
Washington University School of Medicine